Active ingredientSelpercatinibCat. No. P-S029-001CAS 2152628-33-4Family · Pharmaceutical analytical standards
Selpercatinib
A RET kinase inhibitor, approved in 2020 in the United States and in 2021 in Europe for tumours with RET gene alterations, such as some non-small cell lung cancers and thyroid cancers. This family brings together the active ingredient and labelled standards.
Did you know?It was the first therapy approved specifically for cancers with RET alterations, and in 2022 it gained a 'tissue-agnostic' US indication: for any solid tumour with a RET fusion, whatever the organ.
Go to the active ingredient →Active ingredientSelpercatinibCat. No. P-S029-001CAS 2152628-33-4
Isotopically labelledSelpercatinib-13C-d3Cat. No. P-S029-002No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.